arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Innoviva, Inc.

INVA
$20.50 ▼ -0.60 (-2.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
83
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Innoviva, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.5B
Dividend Yield
Revenue Growth 10.6%
Op. Margin 38.9%
ROIC 1.9%
FCF / Share $0.47
Trailing P/E 8.1x
Price / Book 1.1x
FCF Yield 2.3%
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$97.99M
↑ +10.6%
Net Income Profit after all expenses
$186.59M
↑ +500.6%
Operating Margin Operating profit as % of sales
38.9%
↑ +14.5% 93th
FCF / Share Free cash flow per share
$0.47
↓ -39.5%
Long-Term Debt Long-term obligations
$258.10M
— +0.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
97
Returns
89
Financial Health
76
Cash Quality
50

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters